Clinical Trial Update: Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed the combination of arsenic trioxide and ascorbic acid with bortezomib, thalidomide, and dexamethasone in patients with relapsed or r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Ascorbic acid (Vitamin C)
• DEXAMETHASONE (Dexamethasone)
• Thalomid (thalidomide)
• Trisenox (arsenic trioxide)
• Velcade (bortezomib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: COMPLETED